BSE filing, NSE: LINCOLN. Summary written from the filing by ALFA Finder's alert engine.
Lincoln Pharmaceuticals Ltd: key numbers
- Share price
- ₹508.00
- Market cap
- ₹1,018 Cr
- Revenue (annual)
- ₹671.0 Cr
- Net profit (annual)
- ₹87.89 Cr
- P/E (TTM)
- 10.5×Sector 46.1×
- Promoter holding
- 49.78%+0.00% QoQ
- FII holding
- 4.55%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Lincoln Pharmaceuticals Ltd
All →Lincoln Pharmaceuticals Q2 FY27 Results: Net Profit ₹20.4 Cr, Up 2.0% YoY
Lincoln Pharmaceuticals Ltd reported revenue from operations of ₹191.3 Cr (+17.1% YoY) and net profit of ₹20.4 Cr (+2.0% YoY) for Q2 FY27.
- Key figure
- Net profit ₹20.4 Cr · +2.0% YoY
Lincoln Pharmaceuticals Other Announcement
Lincoln Pharmaceuticals Ltd has filed its quarterly shareholding pattern statement for the period ended September 30, 2026, as required under SEBI regulations.
Lincoln Pharmaceuticals Management Change
Lincoln Pharmaceuticals Ltd announced the resignation of Mr. Pradeep Kumar Yadav, Senior General Manager - Quality Assurance, effective October 17, 2026.
Lincoln Pharmaceuticals Annual General Meeting
Lincoln Pharmaceuticals submitted the minutes and voting results of its 32nd Annual General Meeting held on September 30, 2026. The meeting concluded successfully.
Lincoln Pharmaceuticals Annual General Meeting
Lincoln Pharmaceuticals held its 32nd Annual General Meeting on September 30, 2026, where shareholders considered financial statements, dividends, and director reappointments.
Lincoln Pharmaceuticals Management Change
Lincoln Pharmaceuticals announced the resignation of Mr. Manoj Rai, Sr. General Manager (Head QA), a Senior Management Personnel. He departs effective 24 September 2026 for personal reasons.
Other board meeting date announcements
All →Mehta Securities Board Meeting Date
Mehta Securities has scheduled a board meeting on 6 November 2026 to consider unaudited standalone results for the quarter and half year ended 30 September 2026. The trading window stays closed from 1 October 2026 until 48 hours after results.
Mehta Integrated Finance Board Meeting Date
Mehta Integrated Finance scheduled a board meeting on November 6, 2026 to approve half-year results. The trading window remains closed until results are declared.
Sanjivani Paranteral Board Meeting Date
Sanjivani Paranteral will hold a board meeting on 5 November 2026 to approve Q2 unaudited results. The agenda is only proposed until the meeting is held.
Kalpataru Projects International Board Meeting Date
Kalpataru Projects will hold a board meeting on November 5, 2026 to approve quarterly and half-year results. An investor call follows on November 6, and the trading window stays closed.
NACDAC Infrastructure Board Meeting Date
NACDAC Infrastructure will hold a board meeting on November 4, 2026 to approve unaudited standalone half-year results ended September 30, 2026. Trading window remains closed until 48 hours after declaration.
Deep Health AI India Board Meeting Date
Deep Health AI will hold a board meeting on 3 November 2026 for unaudited quarterly and half-year results. Trading window stays closed until 48 hours after results.